This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Establishment and characterization of novel high mucus-producing lung tumoroids derived from a patient with pulmonary solid adenocarcinoma
Human Cell Open Access 17 April 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Passaro, A. et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase 3 MARIPOSA-2 study. Ann Oncol. 21, https://doi.org/10.1016/j.annonc.2023.10.117 (2023)
Ahn, M.-J. et al. Tarlatamab for patients with previously treated small-cell lung cancer. N. Engl. J. Med. 20, https://doi.org/10.1056/NEJMoa2307980 (2023)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sidaway, P. From ESMO 2023: advances in lung cancer. Nat Rev Clin Oncol 21, 4 (2024). https://doi.org/10.1038/s41571-023-00838-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-023-00838-y